RBC Capital Downgrades Marinus Pharmaceuticals (MRNS) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Oppenheimer Downgrades Marinus Pharmaceuticals (MRNS) to Perform
June 14, 2016 7:23 AM EDTOppenheimer downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Outperform to Perform.
For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.
Shares of Marinus Pharmaceuticals closed at $1.62 yesterday.
... MoreStifel Downgrades Marinus Pharmaceuticals (MRNS) to Hold
June 14, 2016 7:02 AM EDTStifel downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Buy to Hold and removed its price target (prior $16.00).
For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.
Shares of Marinus Pharmaceuticals closed at $1.62 yesterday.
... MoreStifel Downgrades Marinus Pharmaceuticals (MRNS) to Hold
June 13, 2016 11:43 AM EDTStifel downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Buy to Hold after the company announced that the Phase III study with ganaxolone in focal onset epilepsy patients did not meet the primary endpoint
Analyst Thomas Shrader commented, "As a result Marinus has made the... More
Marinus Pharma (MRNS) Announces Ganaxolone Phase 3 Missed Primary Endpoint in Adult Focal Onset Seizures
June 13, 2016 7:31 AM EDTMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its... More
